摘要
目的探讨紫杉醇(PTX)或多西紫杉醇(TXT)与氟尿嘧啶(5-FU)/或顺铂(DDP)(简称PCF或DCF方案)治疗进展期胃癌(AGC)的疗效及安全性和生存情况。方法94例AGC患者根据不同化疗方案分为两组。PCF组50例,PTX35～50mg/m2,3h静滴,第1,8,15天;5-FU750mg/m2,持续静滴,第1～5天;DDP20mg/m2,2h静滴,第1～5天。DCF组44例,TXT35mg/m2,1h静滴,第1,8,15天;5-FU及DDP用量、用法与PCF组相同。化疗周期均为28d,两周期后评判近期疗效、安全性,持续随访远期疗效。结果PCF组总有效率(ORR)48.0%,疾病控制率(DCR)82.0%;中位生存期(MST)10.8个月,1年生存率36.0%;DCF组ORR45.5%,DCR81.8%;MST9.9个月、1年生存率34.1%;两组近远期疗效的差异无统计学意义。Ⅲ～Ⅳ级毒副反应主要为中性粒细胞减少、恶心呕吐及脱发。Ⅳ级中性粒细胞减少及贫血总发生率,DCF组显著高于PCF组(P<0.05)。结论PCF方案与DCF方案治疗AGC,疗效和生存情况相似,毒副反应均可耐受。
Objective To compare the efficacies and toxicities of paclitaxel versus docetaxel and cisplatin/fluorouracil（PCF vs. DCF regimens） in the treatment of patients with advanced gastric cancer（AGC）. Methods Ninety-four cases of AGC were divided into 2 groups according to different regimens. The patients in group PCF（50 cases） received PTX 35-50 mg/m2 iv. gtt. 3 hours, on the 1st, 8th, 15th day, 5-FU 750 mg/m2 continuous infusion, on the 1st to the 5th day, DDP 20 mg/mz iv. gtt. 2 hours,on the 1st to the 5th day every four weeks. The patients in group DCF（44 cases） received TXT 35 mg/ m2 iv. gtt. 1 hour, 5-FU and DDP were the same as PCF regimen. Results Overall response rate was 48. 0% in group PCF and 45.5% in group DCF. Disease control rate was 82.0% in group PCF and 81.8% in group DCF. The median survival time was 10. 8 months in group PCF and 9.9 in group DCF. One-year survival rate was 36. 0% in group PCF and 34. 1% in group DCF. The frequent gradeⅢ～Ⅳtoxicities were bone marrow depression, nausea/vomiting and alopecia. There was a significant difference between two groups in grade Ⅳ neutropenia and grade Ⅰ-Ⅳ anemia （P〈0.05）. Conclusion PCF and DCF regimens have similar response rate and survival for advanced gastric cancer and side effects of both regimens are tolerable.
出处
《江苏医药》
CAS
CSCD
北大核心
2009年第8期893-895,共3页
Jiangsu Medical Journal
关键词
紫杉醇
多西紫杉醇
胃癌
化疗
Paclitaxel
Docetaxel
Stomach cancinoma
Chemotherapy
